Completed PHASE1 INTERVENTIONAL 2-arm NCT01156779

Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects (SR-Exenatide)

A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects

Sponsor: Dong-A Pharmaceutical Co., Ltd.

Conditions Diabetes Mellitus

Interventions SR-exenatide

Updated 6 times since 2017 Last updated: Aug 12, 2013 Started: Jul 31, 2010 Primary completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetes Mellitus and is currently completed. Dong-A Pharmaceutical Co., Ltd. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A Pharmaceutical Co., Ltd.

Data source: Dong-A ST Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea